## Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

AVEO PHAR Form 4 February 05, 2	RMACEUTICA 2015	LS INC								
FORM Check this	sbox	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								
if no longer subject to Section 16. Form 4 or	51AIEN 5.	AENT OF	Estimated burden hou response	urs per						
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)									
1. Name and Address of Reporting Person <u>*</u> Needle Michael N			2. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS INC [AVEO]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O AVEO I INC., 650 E.	3. Date of Earliest Transaction (Month/Day/Year) 02/03/2015				Director 10% Owner X Officer (give title Other (specify below) Defined to the provided of the provided o					
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRIDO	GE, MA 02142						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	2. Transaction Date Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Domindary Deres	at on a concepta l'ar	for each -1	on of ac-				or indirectly			
Kenninder: Kepo	rt on a separate line		ass of sec	unues dene	Perso inforr requi	ons who res nation cont red to resp	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amou
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securi

number.

## Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	(D)	(Month/Day/	Year)	(Instr. 3 and	4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo Num Shar
Stock Option (right-to-buy)	\$ 1.07	02/03/2015		А	500,000		<u>(1)</u>	02/03/2025	Common Stock	500

## **Reporting Owners**

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Needle Michael N C/O AVEO PHARMACEUTICALS, INC. 650 E. KENDALL STREET CAMBRIDGE, MA 02142			Chief Medical Officer	
Signatures				
/s/Joseph D. Vittiglio, Esq., attorney-in-fact	02/05	5/2015		
**Signature of Reporting Person	Γ	Date		

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option will vest as to 25% of the shares on January 9, 2016 and in thirty-six equal monthly installments thereafter as to the remaining shares through January 9, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.